



GlaxoSmithKline Consumer Healthcare Ltd.
24-25 Floor, One Horizon Center
Sector 43, DLF Phase 5, Golf Course Road
Gurugram (Haryana), India - 122002

May 11, 2018

T +91 124 4336500
F +91 124 4336600
E contact.4.gsk@gsk.com
www.gsk.com

The Manager - Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra-Kurla Complex
Bandra (East), Mumbai - 400 051

Dear Sir,

Sub: Audited Financial Results for the year ended March 31, 2018, Intimation of the Book Closure dates, Date of Dividend payment and Annual General Meeting

In accordance with SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015, please note that the Board of Directors of the Company at its meeting held on May 11, 2018, has approved the Audited Financial results for the year ended March 31, 2018, a copy of which is enclosed for your reference and records.

The Board also recommended a Dividend at the rate of Rs. 75/- per equity share of Rs. 10 each. The Dividend, if approved by the shareholders in the ensuing Annual General Meeting scheduled to be held on August 8, 2018, will be paid to those members whose names appear in the Company's Register of Members and to those persons whose names appear as Beneficial owners as per the details to be furnished by National Securities Depository Limited and Central Depository Services (India) Ltd. as at the close of business hours on August 1, 2018. The dividend shall be paid to the entitled Members on or before September 7, 2018.

The Board has approved subject to approval of the Shareholders at the ensuing Annual General Meeting the amendment of the Articles of Association of the Company.

The Register of Members and Share Transfer Books will remain closed from August 2, 2018 to August 8, 2018, both days inclusive, for the purpose of Dividend and Annual General Meeting.

The 58th Annual General Meeting of the members of the Company will be held on Wednesday, August 8, 2018 at 9.30 a.m. at Punjab Public School Auditorium, The Punjab Public School (Senior Wing), Nabha 147 201 (Punjab).

Kindly take the above intimation on your records.

Thanking You

Yours faithfully
for GlaxoSmithKline
Consumer Healthcare Limited

Shanu Saksena
Company Secretary

INDEPENDENT AUDITOR'S REPORT

**TO THE BOARD OF DIRECTORS OF
GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED**

1. We have audited the accompanying Statement of Financial Results of **GlaxoSmithKline Consumer Healthcare Limited** ("the Company") for the year ended March 31, 2018 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related Ind AS financial statements which has been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder ('Ind AS') and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such financial statements.
3. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion.

4. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
 - (i) is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016; and
 - (ii) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India of the net profit and total comprehensive income and other financial information of the Company for the year ended March 31, 2018.

**Deloitte
Haskins & Sells LLP**

5. The Statement includes the results for the quarter ended March 31, 2018 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us.

For **DELOITTE HASKINS & SELLS LLP**
Chartered Accountants
(Firm's Registration No. 117366W/W-100018)


Manjula Banerji
Partner

(Membership No. 086423)

Gurugram, May 11, 2018


On



GlaxoSmithKline Consumer Healthcare Ltd.
24-25 Floor, One Horizon Center
Sector 43, DLF Phase 5, Golf Course Road
Gurugram (Haryana), India - 122002

May 11, 2018

T +91 124 4336500
F +91 124 4336600
E contact.4.gsk@gsk.com
www.gsk.com

The Manager - Listing Department
National Stock Exchange of India Ltd.
Exchange Plaza, Bandra-Kurla Complex
Bandra (East), Mumbai - 400 051

Dear Sir,

Sub: Declaration in terms of regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015

In terms of second proviso to regulation 33(3)(d) of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015, we confirm that the Auditors have given an Unmodified Opinion on the Annual Audited Financial Results of the Company for the financial year 2017- 2018.

Kindly take the above intimation on your records.

Thanking You

Yours faithfully
for GlaxoSmithKline
Consumer Healthcare Limited

Vivek Anand
Director Finance & CFO

GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED

Regd. Office: Patiala Road, Nabha - 147 201 (Punjab).

Head Office: 24th Floor, One Horizon Centre, DLF Phase 5, Golf Course Road, Gurugram- 122 002, Haryana.

Tel. No. 01765-306400; Fax No. 01765-220642



CIN: L24231PB1958PLC002257

Email ID: investor.2.co@gsk.com

Website: www.gsk-ch.in

(Rs. in Lakhs)					
Statement of Financial Results for the quarter and year ended March 31, 2018					
Particulars	For the quarter ended			For the year ended	
	31/03/2018	31/12/2017	31/03/2017	31/03/2018	31/03/2017
	Audited (Refer Note 6)	Unaudited	Audited (Refer Note 6)	Audited	Audited
1 Income					
(a) Revenue from operations	11,79,58	10,38,18	12,09,70	43,77,05	44,25,91
(b) Other income	84,17	60,67	70,02	2,57,41	2,39,06
Total Income	12,63,75	10,98,85	12,79,72	46,34,46	46,64,97
2 Expenses					
(a) Cost of materials consumed	3,15,90	3,13,71	2,99,72	12,51,96	11,50,75
(b) Purchase of stock-in-trade	32,53	34,96	47,19	1,39,64	1,53,85
(c) Changes in inventories of work-in-progress, stock-in-trade and finished goods	25,27	(26,34)	29,52	40,98	(7,66)
(d) Excise duty	-	-	1,06,89	60,54	4,34,63
(e) Employee benefits expense	1,37,59	1,31,75	1,02,31	5,27,73	4,50,86
(f) Depreciation and amortisation expense	14,54	15,14	17,70	64,37	64,18
(g) Other expenses					
(i) Advertising and promotion	1,69,26	1,12,53	1,73,52	5,46,73	5,14,67
(ii) Others	2,49,00	2,64,05	2,32,54	9,26,12	8,90,49
(h) Finance costs	77	17	87	2,03	2,78
Total Expenses	9,44,86	8,45,97	10,10,26	35,60,10	36,54,55
3 Profit before tax (1-2)	3,18,89	2,52,88	2,69,46	10,74,36	10,10,42
4 Income tax expense					
(a) Current tax	1,04,25	85,18	88,01	3,61,91	3,70,24
(b) Deferred tax	2,83	4,04	5,57	12,35	(16,50)
Total tax expense	1,07,08	89,22	93,58	3,74,26	3,53,74
5 Profit for the period (3-4)	2,11,81	1,63,66	1,75,88	7,00,10	6,56,68
6 Other comprehensive income					
(i) Items that will not be reclassified to profit or loss					
Remeasurements of post-employment benefit obligations	12,66	2,95	4,18	25,49	33,03
(ii) Income tax relating to items that will not be reclassified to profit or loss	(4,38)	(1,02)	(1,45)	(8,82)	(11,43)
Total other comprehensive income, net of income tax	8,28	1,93	2,73	16,67	21,60
7 Total comprehensive income for the period (5+6)	2,20,09	1,65,59	1,78,61	7,16,77	6,78,28
8 Paid up equity share capital	42,06	42,06	42,06	42,06	42,06
(Face value of Equity Shares)	10	10	10	10	10
9 Earnings per share (of Rs 10/- each) (not annualised):					
(a) Basic	50.36	38.91	41.82	166.47	156.15
(b) Diluted	50.36	38.91	41.82	166.47	156.15



NS Ahija

GLAXOSMITHKLINE CONSUMER HEALTHCARE LIMITED

Regd. Office: Patiala Road, Nabha - 147 201 (Punjab).

Head Office: 24th Floor, One Horizon Centre, DLF Phase 5, Golf Course Road, Gurugram-122 002, Haryana.

Tel. No. 01765-306400; Fax No. 01765-220642



CIN: L24231PB1958PLC002257

Email ID: investor.2.co@gsk.com

Website: www.gsk-ch.in

(Rs. in Lakhs)

Statement of assets and liabilities		
Particulars	As at March 31, 2018 (Audited)	As at March 31, 2017 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	4,75,38	4,87,04
Capital work-in-progress	35,71	49,18
Intangible assets	15	39
Intangible assets under development	2,54	8,49
Financial assets		
i. Loans	16,28	30,57
ii. Other financial assets	21,71	21,71
Deferred tax assets (net)	1,15,45	1,27,80
Income tax assets (net)	1,77,91	81,70
Other non-current assets	5,53	8,67
Total non-current assets	8,50,66	8,15,55
Current assets		
Inventories	4,09,42	4,61,15
Financial assets		
i. Trade receivables	2,78,72	3,21,00
ii. Cash and cash equivalents	6,14,10	7,00,91
iii. Bank balances other than (ii) above	29,71,09	23,86,46
iv. Loans	14,80	11,68
v. Other financial assets	1,77,66	1,48,75
Employee Benefits	15,83	7,29
Other current assets	80,38	1,01,89
Total current assets	45,62,00	41,39,13
Total assets	54,12,66	49,54,68
EQUITY AND LIABILITIES		
Equity		
Equity share capital	42,06	42,06
Other equity	34,43,06	30,80,61
Total equity	34,85,12	31,22,67
LIABILITIES		
Non-current liabilities		
Provisions	1,25,41	1,71,62
Employee benefit obligations	59,54	64,77
Total non-current liabilities	1,84,95	2,36,39
Current liabilities		
Financial Liabilities		
(i) Trade payables	10,34,73	8,75,66
(ii) Other financial liabilities	3,11,09	3,26,84
Provisions	2,77,59	2,64,16
Employee benefit obligations	36,79	40,63
Other current liabilities	82,39	88,33
Total current liabilities	17,42,59	15,95,62
Total liabilities	19,27,54	18,32,01
Total equity and liabilities	54,12,66	49,54,68




NS Gupta

Notes to the financial results:

1. The above results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors in their meeting held on May 11, 2018 and were subjected to an audit by the statutory auditors.
2. The above results have been prepared in accordance with the Indian Accounting Standard (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. Amounts for the quarter and year ended March 31, 2017 and as at March 31, 2017 were audited by previous auditors - Price Waterhouse.
3. Consequent to introduction of Goods and Services (GST) with effect from July 01, 2017. Central Excise, Value Added Tax (VAT) etc. have been subsumed into GST. In accordance with Indian Accounting Standard – 18 on Revenue and Schedule III of the Companies Act, 2013, unlike Excise Duties, levies like GST, VAT, etc. are not part of Revenue. Accordingly, the figures for the periods upto June 30, 2017 are not strictly relatable to those thereafter.
4. As the Company's business activity falls within a single operating segment namely "Nutrition", the disclosure requirements of Ind AS 108 "Operating segment" prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder, are not applicable.
5. The Board of Directors at their meeting considered and recommended a final dividend aggregating Rs. 3,15,42 lakhs @ Rs. 75 per share (nominal value Rs. 10 per share) for the financial year 2017-18 (final dividend paid for previous year Rs. 2,94,39 lakhs @ Rs. 70 per share).
6. The figures of the quarter ended March 31, 2018 and March 31, 2017 are the balancing figures between the audited figures in respect of the full financial year and the published unaudited year to date figures upto the third quarter of respective financial year which was subjected to limited review.
7. The figures for the previous periods have been reclassified/regrouped wherever required to confirm to the current periods presentation/classification. These are not material and do not affect the previously reported net profit or equity.

Place: Gurugram
Date : May 11, 2018

ON BEHALF OF THE BOARD OF DIRECTORS



Navneet Saluja
Managing Director
DIN: 2183350



